Compare MARPS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MARPS | APRE |
|---|---|---|
| Founded | 1956 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 11.5M |
| IPO Year | N/A | 2019 |
| Metric | MARPS | APRE |
|---|---|---|
| Price | $4.38 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 10.7K | ★ 116.3K |
| Earning Date | 02-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.05 | $0.55 |
| 52 Week High | $6.49 | $2.22 |
| Indicator | MARPS | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 50.56 |
| Support Level | $4.16 | $0.75 |
| Resistance Level | $4.88 | $0.81 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 24.29 | 76.10 |
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.